Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure

被引:2
作者
Monzo, Luca [1 ,2 ,3 ]
Jarolim, Petr [4 ]
Borlaug, Barry A. [5 ]
Benes, Jan [1 ]
Jurcova, Ivana [1 ]
Jenca, Dominik [1 ]
Kroupova, Katerina [1 ]
Wohlfahrt, Peter [1 ]
Kotrc, Martin [1 ]
Melenovsky, Vojtech [1 ]
机构
[1] Inst Clin & Expt Med IKEM, Prague, Czech Republic
[2] Univ Lorraine, Ctr Invest Clin Plurithemat 1433, INSERM, Inserm U1116,CHRU Nancy, Nancy, France
[3] F CRIN INI CRCT, Nancy, France
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[5] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
anorexia; cachexia; growth differentiation factor-15; heart failure; right ventricular dysfunction; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; ADIPOSE-TISSUE; CACHEXIA; GDF15; PROGNOSIS; DISEASE; ECHOCARDIOGRAPHY; METABOLISM; MORTALITY;
D O I
10.1016/j.jchf.2024.10.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. OBJECTIVES This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF). METHODS In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 +/- 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization. RESULTS The median GDF-15 level was 1,503 ng/L (Q1-Q3: 955-2,332 ng/L) (reference range: <1,200 ng/L). Higher GDF-15 levels were associated with more prevalent anorexia and cachexia. Patients with higher GDF-15 had increased circulating free fatty acids and beta-hydroxybutyrate, lower albumin, cholesterol, and insulin/glucagon ratio, consistent with a catabolic state. Patients with higher GDF-15 had worse congestion and more severe right ventricular dysfunction. In multivariable Cox analysis, elevated GDF-15 was independently associated with risk of the combined endpoint of death, urgent transplantation, or left ventricular assist device implantation, even after adjusting for coexisting anorexia and cachexia (T3 vs T1 HR: 2.31 [95% CI: 1.47-3.66]; P < 0.001). CONCLUSIONS In patients with advanced HFrEF, elevated circulating GDF-15 levels are associated with a higher prevalence of anorexia and cachexia, right ventricular dysfunction, and congestion, as well as an independently increased risk of adverse events. Further studies are warranted to determine whether therapies altering GDF-15 signaling pathways can affect metabolic status and clinical outcomes in advanced HFrEF. (c) 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:315 / 329
页数:15
相关论文
共 65 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK
    Aguilar-Recarte, David
    Barroso, Emma
    Guma, Anna
    Pizarro-Delgado, Javier
    Pena, Lucia
    Ruart, Maria
    Palomer, Xavier
    Wahli, Walter
    Vazquez-Carrera, Manuel
    [J]. CELL REPORTS, 2021, 36 (06):
  • [3] Novel biomarkers in chronic heart failure
    Ahmad, Tariq
    Fiuzat, Mona
    Felker, G. Michael
    O'Connor, Christopher
    [J]. NATURE REVIEWS CARDIOLOGY, 2012, 9 (06) : 347 - 359
  • [4] Neutralization of GDF15 Prevents Anorexia and Weight Loss in the Monocrotaline-Induced Cardiac Cachexia Rat Model
    Albuquerque, Bina
    Chen, Xian
    Hirenallur-Shanthappa, Dinesh
    Zhao, Yang
    Stansfield, John C.
    Zhang, Bei B.
    Sheikh, Abdul
    Wu, Zhidan
    [J]. CELLS, 2022, 11 (07)
  • [5] Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial
    Anand, Inder S.
    Kempf, Tibor
    Rector, Thomas S.
    Tapken, Heike
    Allhoff, Tim
    Jantzen, Franziska
    Kuskowski, Michael
    Cohn, Jay N.
    Drexler, Helmut
    Wollert, Kai C.
    [J]. CIRCULATION, 2010, 122 (14) : 1387 - +
  • [6] Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure
    Anker, SD
    Egerer, KR
    Volk, HD
    Kox, WJ
    PooleWilson, PA
    Coats, AJS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (10) : 1426 - &
  • [7] Wasting as independent risk factor for mortality in chronic heart failure
    Anker, SD
    Ponikowski, P
    Varney, S
    Chua, TP
    Clark, AL
    WebbPeploe, KM
    Harrington, D
    Kox, WJ
    PooleWilson, PA
    Coats, AJS
    [J]. LANCET, 1997, 349 (9058) : 1050 - 1053
  • [8] GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss
    Borner, Tito
    Wald, Hallie S.
    Ghidewon, Misgana Y.
    Zhang, Bei
    Wu, Zhidan
    De Jonghe, Bart C.
    Breen, Danna
    Grill, Harvey J.
    [J]. CELL REPORTS, 2020, 31 (03):
  • [9] Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial
    Bouabdallaoui, Nadia
    Claggett, Brian
    Zile, Michael R.
    McMurray, John J. V.
    O'Meara, Eileen
    Packer, Milton
    Prescott, Margarett F.
    Swedberg, Karl
    Solomon, Scott D.
    Rouleau, Jean L.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (12) : 1701 - 1709
  • [10] GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates
    Breen, Danna M.
    Kim, Hanna
    Bennett, Donald
    Calle, Roberto A.
    Collins, Susie
    Esquejo, Ryan M.
    He, Tao
    Joaquim, Stephanie
    Joyce, Alison
    Lambert, Matthew
    Lin, Laura
    Pettersen, Betty
    Qiao, Shuxi
    Rossulek, Michelle
    Weber, Gregory
    Wu, Zhidan
    Zhang, Bei B.
    Birnbaum, Morris J.
    [J]. CELL METABOLISM, 2020, 32 (06) : 938 - 950.e6